医科院基础所曹雪涛院士实验室成立于2011年，目前实验室有五位高级职称科研人员，实验成员主要由充满创新活力的青年科技人员组成，并与英国牛津大学、瑞典卡罗林斯卡医学院等多个国内外著名实验室有着稳定的合作与交流。课题组在天然免疫与炎症疾病领域开展了创新性研究，自主发现了病原体感染机体导致炎症发生的关键性免疫分子、促进炎症消退的表观遗传调控因子、控制免疫应答适度终止从而避免自身免疫性炎症疾病发生的关键性因素，为下一步抗炎药物的研发与产业化奠定了基础；创新性地发现了导致肿瘤免疫逃逸与免疫抑制的分子、鉴定出了判断肿瘤转移（包括肿瘤选择性肺转移、乳腺癌选择性淋巴结转移）与患者预后的关键分子、研制了肿瘤免疫治疗的新型杀伤性细胞与癌症疫苗，为癌症治疗提供了新方案新策略与抗癌药物研发的新型潜在靶标。这些原创性科技成果完全立足于国内完成，并发表于Cell、Nature、Science、Immunity、Nature Immunology、Cancer Cell、PNAS等国际顶尖学术期刊。实验室目前承担了包括国家自然科学基金委基础科学中心项目、中国医学科学院医学与健康创新工程项目等在内的多个课题研究。实验室建立了新型免疫分子发现与功能性筛选技术、免疫炎症疾病研究模型、肿瘤免疫治疗研究体系、生物大数据分析手段等多个先进平台，有望继续做出原创性基础研究工作和实用性转化应用成果。

国家自然基金委科学中心项目（天然免疫与炎症疾病，82388201），在研，主持

中国医学科学院医学与健康科技创新工程重大协同创新项目（免疫应答和炎症调控新机制与疾病免疫治疗，2021-I2M-1-017），在研，主持

（1）研究肿瘤免疫逃逸与免疫治疗抵抗的机制，为临床肿瘤免疫治疗提供了新的治疗靶点和干预策略；

（2）研究天然免疫识别及其调控机制：包括鉴定新型天然免疫受体及其炎症调控功能，创建炎症启动和发生新模式，探究免疫代谢物与天然免疫的表观调控机制等；

（3）研究细胞死亡分子机器的结构基础与免疫炎症功能： 包括鉴定新的细胞死亡受体，揭示新的细胞死亡方式，寻找新的细胞死亡相关治疗靶点等；

（4）利用多组学和大数据分析寻找和鉴定在天然免疫和肿瘤免疫中发挥关键作用的分子和细胞亚群；

（5）利用人工智能技术分析蛋白互相作用，筛选新靶点特异性抗体、TCR和CAR，从而设计新型高效肿瘤免疫疗法；

（6）利用化学技术对小分子化合物进行结构优化，筛选免疫信号通路关键分子的激动剂或拮抗剂，开发具有临床转化潜力的小分子药物。

1. Lei Wang#, Mingyue Wen#, Xuetao Cao*. Nuclear hnRNPA2B1 initiates and amplifies the innate immune response to DNA viruses. Science, 2019, 365, 6454.

2. Yang Liu#, Yuling You, Zhike Lu, Jiang Yang, Panpan Li, Lun Liu, Henan Xu, Yamei Niu, Xuetao Cao*. N6-methyladenosine RNA modification–mediated cellular metabolism rewiring inhibits viral replication. Science, 2019, 365, 1171–1176.

3. Qicong Shen#, Qian Zhang#, Yang Shi, Qingzhu Shi, Yanyan Jiang,Yan Gu, Zhiqing Li, Xia Li, Kai Zhao, Chunmei Wang, Nan Li, Xuetao Cao*. Tet2 promotes pathogen infection-induced myelopoiesis through mRNA oxidation. Nature, 2018, 554, 123–127.

4. Minghong Jiang#, Shikun Zhang#, Zongheng Yang, Hongyu Lin, JunZhu, Lun Liu, Wendie Wang, Shuo Liu, Wei Liu, Yuanwu Ma, Lianfeng Zhang, Xuetao Cao*. Self-Recognition of anInducible Host lncRNA by RIG-I Feedback Restricts Innate Immune Response. Cell, 2018, 173, 906–919.

5. Xiaoqing Xu#, Jia Xu, Jiacheng Wu, Ye Hu, Yanmei Han, Yan Gu, Kai Zhao, QianZhang, Xingguang Liu, Juan Liu, Bing Liu, Xuetao Cao*. Phosphorylation-Mediated IFN-γR2 MembraneTranslocation Is Required to Activate Macrophage Innate Response. Cell, 2018, 175, 1336–1351.

6. Yanmei Han#, Qiuyan Liu, Jin Hou, Yan Gu, Yi Zhang, Zhubo Chen, Jia Fan,Weiping Zhou, Shuangjian Qiu, Yonghong Zhang, Tao Dong, Ning Li, Zhengping Jiang, Ha Zhu, Qian Zhang, Yuanwu Ma, Lianfeng Zhang, Qingqing Wang, Yizhi Yu, Nan Li, Xuetao Cao*. Tumor-Induced Generation of Splenic Erythroblast-likeTer-Cells Promotes Tumor Progression. Cell, 2018, 173(3), 634–648.

7. Qingzhu Shi#, Qicong Shen#, Yanfang Liu, Yang Shi, Wenwen Huang, Xi Wang, Zhiqing Li, Yangyang Chai, Hao Wang, Xiangjia Hu, Nan Li, Qian Zhang*, Xuetao Cao*. Increased glucose metabolism in TAMs fuelsO-GlcNAcylation of lysosomal Cathepsin B to promote cancer metastasis and chemoresistance. Cancer Cell, 2022, 40(10), 1207-1222.

8. Yujia Wang#, Pin Wang, Yunkai Zhang, Junfang Xu, Zhiqing Li, Zemeng Li, Zhongcheng Zhou, Lin Liu, Xuetao Cao*. Decreased Expression of the Host Long-Noncoding RNA-GM Facilitates Viral Escapeby Inhibiting the Kinase activity TBK1 via S-glutathionylation. Immunity, 2020, 53, 1168-1181.

9. Juan Liu#, Xiaomin Zhang, Kun Chen, Yujie Cheng, Shuxun Liu, Meng Xia,Yali Chen, Ha Zhu, Zhiqing Li, XuetaoCao*. CCR7 Chemokine Receptor-Inducible lnc-Dpf3 Restrains Dendritic Cell Migration by Inhibiting HIF-1α-Mediated Glycolysis. Immunity, 2019, 50, 600–615.

10. Zhiqing Li#, Shuxun Liu, Junfang Xu, Xiang Zhang, Dan Han, Juan Liu, MengXia, Lin Yi, Qicong Shen, Sheng Xu, Linrong Lu, Xuetao Cao*. Adult Connective Tissue-Resident Mast Cells Originate from Late Erythro-Myeloid Progenitors. Immunity, 2018, 49, 640–653.

11. Henan Xu#, Yan Jiang, Xiaoqing Xu, Xiaoping Su, Yang Liu, Yuanwu Ma, YongZhao, Zhongyang Shen, Bo Huang, Xuetao Cao*. Inducible degradation of lncRNA Sros1 promotes IFN-γ-mediated activation of innate immune responses by stabilizing Stat1 mRNA. Nature Immunology, 2019, 20,1621–1630.

12. Hongyu Lin#, Minghong Jiang#, Lun Liu, Zongheng Yang, Zhongfei Ma, Shuo Liu, Yuanwu Ma, Lianfeng Zhang, Xuetao Cao*. The long noncoding RNA Lnczc3h7a promotes TRIM25-mediated RIG-I antiviral innate immune response. Nature Immunology, 2019, 20, 812–823.

13. Yan Gu#, Yanfang Liu#, Li Fu, Lili Zhai, Jie Zhu, Yanmei Han, Yingming Jiang, Yi Zhang, Peng Zhang, Zhengping Jiang, Xiang Zhang, Xuetao Cao*. Tumor-educated B cells selectively promote breast cancer lymph node metastasis by HSPA4-targeting IgG. Nature Medicine, 2019, 25(2), 312-322.

14. Hantao Lou#, Jianqing Zheng#, Xiaohang Leo Fang, Zhu Liang, Meihan Zhang, Yu Chen, Chunmei Wang, Xuetao Cao*. Deep learning-based rapid generation of broadly reactive antibodies against SARS-CoV-2 and its Omicron variant. Cell Research, 2022,1-3.

15. Yumei Zhou#, Mengxuan Li, Yiquan Xue, Zhiqing Li, Weitao Wen, Xingguang Liu, Yuanwu Ma, Lianfeng Zhang, Zhongyang Shen, Xuetao Cao*. Interferon-inducible cytoplasmiclncLrrc55-AS promotes antiviral innate responses by strengthening IRF3 phosphorylation. Cell Research, 2019, 29, 641–654.

16. Xingguang Liu#, Peng Zhang, Yunkai Zhang, Zheng Wang, Sheng Xu, Yingke Li, Wanwan Huai, Qingqing Zhou, Xiang Chen, Xi Chen, Nan Li, Peng Wang, Yunsen Li, Xuetao Cao*. GlycolipidiGb3 feedback amplifies innate immune responses via CD1d reverse signaling. Cell Research, 2019, 29, 42–53.

17. Jun Zhou#, Jiaqi Liu#, Bingjing Wang, Nan Li, JuanLiu, Yanmei Han, Xuetao Cao*. Eosinophils promote CD8+ T cell memorygeneration to potentiate anti-bacterial immunity. Signal Transduction & Target Therapy, 2024 Feb 28;9(1):43.

18. Yang Liu#*, Renjie Song, Lu Zhao, Zhike Lu, Yini Li, Xinyi Zhan, Fengjiao Lu, Jiang Yang, Yamei Niu, Xuetao Cao*. m6 A demethylase ALKBH5 isrequired for antibacterial innate defense by intrinsic motivation of neutrophil migration. Signal Transduction & Target Therapy, 2022, 7(1), 194.

19. Ha Zhu#, Kun Chen, Yali Chen, Juan Liu, Xiaomin Zhang, Yumei Zhou, Qiuyan Liu, Bingjing Wang, Taoyong Chen, Xuetao Cao*. RNA-binding protein ZCCHC4 promotes human cancer chemoresistance by disrupting DNA-damage-induced apoptosis. Signal Transduction & Target Therapy, 2022, 7(1), 240.

20. JiachengWu#, Xiaoqing Xu#, Jiaqi Duan, Yangyang Chai, JiayingSong, Dongsheng Gong, Bingjing Wang, Ye Hu, TaotaoHan, Yuanyuan Ding, Yin Liu, Jingnan Li, Xuetao Cao*. EFHD2suppresses intestinal inflammation by blocking intestinal epithelial cell TNFR1internalization and cell death. Nature Communications, 2024 Feb 12;15(1):1282.

21. YanJiang#, SiqiSun, Yuan Quan, Xin Wang, Yuling You, Xiao Zhang, YueZhang, Yin Liu, Bingjing Wang, Henan Xu*, XuetaoCao*.Nuclear RPSA senses viral nucleic acids to promote the innate inflammatoryresponse. Nature Communications, 2023 Dec 20;14(1):8455.

22. Huamin Wang#, Xiang Hu#, Mingyan Huang, Juan Liu, Yan Gu, Lijia Ma, Qi Zhou, Xuetao Cao*. Mettl3-mediated mRNA m6A methylation promotes dendritic cellactivation. Nature Communications, 2019, 10, 1898.

23. Wanwan Huai#, Xingguang Liu, Chunmei Wang, Yunkai Zhang, Xi Chen, Xiang Chen, Sheng Xu, Tim Thomas, Nan Li, Xuetao Cao*. KAT8 selectively inhibits antiviral immunity by acetylating IRF3. Journal of Experimental Medicine, 2019, 216, 772–785.

24. YaliChen#, Kun Chen, Ha Zhu, Hua Qin, Juan Liu, Xuetao Cao*.Methyltransferase Setd2 prevents T cell-mediated autoimmune diseases viaphospholipid remodeling. Proceedings of the National Academy of Sciences, 2024 Feb20;121(8):e2314561121.

25. Zixin Wang#, Jie Zhu, Yanfang Liu, Ziqiao Wang, Xuetao Cao*, Yan Gu*. Tumor-polarized GPX3+ AT2 lung epithelial cells promote premetastatic niche formation. Proceedings of the National Academy of Sciences, 2022, 119(32), e2201899119.

26. Shuo Liu#, Jiaqi Liu, Xue Yang, Minghong Jiang, Qingqing Wang, Lianfeng Zhang, Yuanwu Ma, Zhongyang Shen, Zhigang Tian, Xuetao Cao*. Cis-acting lnc-Cxcl2 restrains neutrophil-mediatedlung inflammation by inhibiting epithelial cell CXCL2 expression in virus infection. Proceedings of the National Academy of Sciences, 2021,118(41), e2108276118.

27. Wei Liu#, Ziqiao Wang, Lun Liu, Zongheng Yang, Shuo Liu, Zhongfei Ma, Yin Liu, Yuanwu Ma, Lianfeng Zhang, Xuan Zhang, Minghong Jiang*, Xuetao Cao*. LncRNA Malat1 inhibition of TDP43 cleavage suppresses IRF3-initiated antiviral innate immunity. Proceedings of the National Academy of Sciences, 2020, 117, 23695–23706.

28. Yuan Zhang#, Xin Wang, Xiao Zhang, Jiaming Wang, Yuanwu Ma, Lianfeng Zhang, Xuetao Cao*. RNA-binding protein YTHDF3 suppresses interferon-dependent antiviral responses by promoting FOXO3 translation. Proceedings of the National Academy of Sciences, 2019, 116, 976–981.

29. JuanLiu#, YujieCheng, XiaominZhang, YaliChen, Ha Zhu, KunChen, ShuxunLiu, ZhiqingLi, XuetaoCao*.Glycosyltransferase Extl1 promotes CCR7-mediated dendritic cell migration torestrain infection and autoimmunity. Cell Reports, 2023Jan 31;42(1):111991. 

30. JunZhu#, ShuoLiu, JialiFang, ZenghuiCui, BingjingWang, YuzhouWang, Lin Liu, QingqingWang, XuetaoCao*.Enzymolysis-basedRNA pull-down identifies YTHDC2 as an inhibitor of antiviral innate response. Cell Reports, 2023 Sep 29;42(10):113192.

31. Wei Liu#, Ziqiao Wang, Shuo Liu, Xuan Zhang, Xuetao Cao*, Minghong Jiang*. RNF138 inhibits late inflammatory gene transcription through degradation of SMARCC1 of the SWI/SNFcomplex. Cell Reports, 2023, 42(2), 112097.

32. Junfang Xu#, Pin Wang, Zemeng Li, Zhiqing Li, Dan Han, Mingyue Wen, Qihang Zhao, Lianfeng Zhang, Yuanwu Ma, Wei Liu, Minghong Jiang, Xuan Zhang, Xuetao Cao*. IRF3-binding lncRNA-ISIR strengthens interferon production in viral infection and autoinflammation. Cell Reports, 2021, 37(5), 109926.

33. Wenkai Zhou#, Jiaming Wang, Xin Wang, Bingjing Wang, Zhehui Zhao, Jie Fu, Yan Wang, Xuan Zhang, Ping Zhu*, Minghong Jiang*, Xuetao Cao*. Degradation of HDAC10 by autophagy promotes IRF3-mediated antiviral innate immune responses. Science Signaling, 2022, 15(765), eabo4356.

34. Yali Chen#, Juan Liu, Xiaomin Zhang, Ha Zhu, Yujia Wang, Zhiqing Li, Yanfang Liu, Shuo Liu, Shuxun Liu, Nan Li, Kun Chen*, Xuetao Cao*. lncRNA-GM targets Foxo1 to promote T cell-mediated autoimmunity. Science Advance, 2022, 8(31), eabn9181.

中国医学科学院免疫治疗中心以曹雪涛教授课题组为研究基地，主要针对恶性肿瘤、感染性疾病、心脑血管疾病、自身免疫性疾病等严重威胁人类健康的重大疾病，建立以“疫苗研发、过继性细胞产品研发、抗体研发、重组蛋白研发”为核心的四大研发平台。目前已形成一个围绕“慢病免疫防治”的基础研究、高新技术研发和临床应用一体化的研究体系。主要基于自主研发的潜在靶点开展肿瘤免疫治疗研究，建立了单B细胞测序抗体研发技术体系和免疫激活分子修饰DC疫苗体系；开展了免疫相关疾病的靶点和免疫治疗预判标志物筛选以及功能研究，揭示了新型的感染和肿瘤的分子发生机制，为临床疾病的防治提供了新的靶点和治疗方式。

中国医学科学院-牛津大学免疫转化中心以曹雪涛教授课题组为研究基地，隶属于中国医学科学院牛津研究所（CAMS-Oxford Institute，COI）。借助中国医学科学院和牛津大学在各自地理区域及学术领域的优势协同，通过定期召开国际学术会议和学术沙龙，组织开展科研人员和师生的交流互访，搭建中英医学科技合作与交流的平台，主要在感染免疫和肿瘤免疫的研究方向与牛津大学展开深入合作。